Navigation Links
Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
Date:3/26/2008

ede and can develop into cervical cancer. The primary cause of such abnormalities is infection with certain HPV types, of which HPV-16 is the most common. In the U.S., these infections are typically discovered through nearly 60 million Pap screens completed each year, at a cost of up to $6 billion. Each year in the U.S., an estimated 1.2 million women are diagnosed with low grade cervical dysplasia, (CIN 1), 300,000 with high grade dysplasia (CIN 2/3) and 2.4 million with atypical squamous cells of undetermined significance (ASCUS). No therapies other than surgery are currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of any type of CIN.

About HspE7:

The company's lead candidate, HspE7, is a novel therapeutic candidate intended for the treatment of precancerous and cancerous lesions caused by the human papillomavirus (HPV), one of the most common sexually transmitted diseases in the world. HspE7 incorporates the proprietary adjuvant, Poly-ICLC, a toll-like receptor-3 (TLR3) agonist. An adjuvant is a substance added to vaccines to improve immune responses against target antigens. HspE7 is derived from Nventa's proprietary CoVal(TM) fusion platform, which uses recombinant DNA technology to covalently fuse stress proteins to target antigens, thereby stimulating cellular immune system responses. Nventa is developing HspE7 for multiple indications.

About Nventa Corporation:

Nventa is developing innovative therapeutics for the treatment of viral infections and cancer, with a focus on diseases caused by the human papillomavirus (HPV). The company is publicly traded on the Toronto Stock Exchange under the symbol NVN. For more information about Nventa, please visit http://www.nventacorp.com.

This press release contains statements which may constitute forward-looking information under applicable Canadian securities legislation or forward-looking statements
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
2. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
3. Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
4. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
5. IDM Pharma Announces Availability of Mifamurtide (L-MTP-PE) Through Compassionate Access Study
6. Valor Medical Announces First Human Implant of Neucrylate AN(TM) for Treatment of Cerebral Aneurysm
7. Medicare Announces Expanded Coverage for Anticoagulation Patients, Opening the Door for More Patients to Test PT/INR at Home
8. Medicare Announces Expanded Coverage for Warfarin Patients Monitoring Clotting Time at Home
9. FluoroPharma Announces Commencement of Phase I Clinical Trial for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET)
10. Emisphere Announces Second Study Demonstrating Dramatic Increases in Absorption of Oral B12 Using eligen(R) Technology at Lower Doses
11. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... YORK and LONDON , ... of market intelligence, MarketResearch.com is pleased to announce the ... and Consultancy focusing on the active pharmaceutical ingredient (API) ... visit: http://www.marketresearch.com/land/publisher.asp?vendorid=4023&progid=86891 . In IQ4I,s ... – Forecast to 2020 , IQ4I ...
(Date:11/26/2014)... YORK , Nov. 25, 2014  Medtronic,s ... Covidien has been widely discussed in the ... it,s also creating a stronger leading player in ... to Kalorama Information.  The healthcare market research firm ... systems will feature a diverse set of solutions ...
(Date:11/26/2014)... 2014  Breckenridge Pharmaceutical, Inc. announced today that ... with Pii (Pharmaceutics International, Inc.) ( Hunt ... Pii expect to develop and commercialize several new ... will develop, manufacture and supply the products, and ... its own label.  The drugs, comprised of four ...
Breaking Medicine Technology:MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 3Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 2Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 3Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with Pharmaceutics International, Inc. 2
... , WILMINGTON, Del., Oct. 16 AstraZeneca ... and Drug Administration (FDA) approved CRESTOR® (rosuvastatin calcium) ... familial hypercholesterolemia (HeFH) when diet therapy fails to reduce ... characterized by high LDL cholesterol (the "bad" cholesterol) and ...
... CITY, Oct. 15 Dynatronics Corporation (Nasdaq: DYNT ) ... a letter from Nasdaq stating that the Company has not ... from Nasdaq. , Nasdaq provides the Company an opportunity to ... panel is authorized to grant up to 180 additional calendar ...
Cached Medicine Technology:U.S. Food and Drug Administration Approves CRESTOR(R) for Use in Pediatric Patients With Heterozygous Familial Hypercholesterolemia 2U.S. Food and Drug Administration Approves CRESTOR(R) for Use in Pediatric Patients With Heterozygous Familial Hypercholesterolemia 3U.S. Food and Drug Administration Approves CRESTOR(R) for Use in Pediatric Patients With Heterozygous Familial Hypercholesterolemia 4
(Date:11/26/2014)... The family foundation of Best Buy founder, ... Research Foundation (Meso Foundation), half of which will be ... Grant Program . The focus area of the Richard ... with organizations that can generate transformational results in education, ... founder and chairman emeritus of Best Buy Co., Inc., ...
(Date:11/26/2014)... German scientists say carbon-based synthetic molecules used in ... looks and acts similar to asbestos-induced mesothelioma. Surviving Mesothelioma ... Click here to read it now. , ... Medicine in Hannover injected 500 lab rats with multi-walled ... developed mesothelioma , how quickly it developed appeared ...
(Date:11/26/2014)... Los Angeles, CA (PRWEB) November 26, 2014 ... Los Angeles orthopedic surgeon Dr. Steven Meier has ... site to offer current and prospective patients an online ... , “We’re really excited to present the new and ... and added features make it easier than ever for ...
(Date:11/26/2014)... 2014 ISI Telemanagement Solutions, Inc., ... been award the 2014 Lync Pioneer Award ... comes as a great honor to ISI, who ... ecosystem. Specifically, ISI offers an integrated collaboration reporting ... communication, including voice, video, Lync IM, and conferencing. ...
(Date:11/26/2014)... 26, 2014 For those with a New ... LES MILLS BODYPUMP™ classes at the University of Colorado ... they've been looking for. The 45- 60 minute classes have ... and Wellness Center fitness club memberships. , LES MILLS BODYPUMP™ ... fast-paced and are aimed at fast results , By ...
Breaking Medicine News(10 mins):Health News:Best Buy Founder’s Family Foundation Donates $100,000 to Organization Fighting Deadly Cancer 2Health News:Best Buy Founder’s Family Foundation Donates $100,000 to Organization Fighting Deadly Cancer 3Health News:Multi-walled Nanotubes Linked to Mesothelioma in New Study, According to Surviving Mesothelioma 2Health News:Los Angeles Orthopedic Surgeon Dr. Steven Meier Announces Relaunch Of Practice Website 2Health News:ISI Telemanagement Solutions, Inc. has been Awarded the 2014 Microsoft Lync Pioneer Award 2Health News:LES MILLS BODYPUMP™ classes come to the University of Colorado Anschutz Health and Wellness Center 2
... found that primitive immune systems of fruit flies may ... that immune memory was not possible for insects. ... Medicine could have implications for new ways of developing ... ,The evidence that a fruit fly's immune ...
... Human embryonic stem cells (hESCs) hold great promise for ... provide evidence// that stem cell-derived nerve cells may integrate ... ,This study was conducted by an international collaboration led ... a member of his lab, Jean-Pyo Lee, Ph.D., of ...
... TVs contain possibly hazardous chemicals called polybrominated diphenyl ethers ... of Standards and Technology and the Environmental Protection Agency ... not yet clear how dangerous these PBDEs are, though ... Their structure is strikingly similar to that of PCBs, ...
... risk of prostate cancer amongst Japanese men by as much ... ,"To our knowledge, this is the first prospective study to ... in Japanese, whose intake of soy food is high," wrote ... ,Over half a million news cases of prostate cancer ...
... team of scientists who have achieved a major breakthrough in ... cancer// tumors in humans. ,Anindya Bagchi, along with ... (CSHL), a private research institute in Long Island, New York, ... cells to misbehave and tumors to form. ,The ...
... Unprocessed cocoa is reported to have huge health benefits ... anesthesia//. This was disclosed by Norman Hollenberg, professor of ... suggests that Epicatechin which is found in high levels ... four major and common diseases of the western world ...
Cached Medicine News:Health News:Flies too Have Immune Memory! 2Health News:Flies too Have Immune Memory! 3Health News:Stem Cells Hold Promise for Treating Neurodegenerative Diseases 2Health News:Stem Cells Hold Promise for Treating Neurodegenerative Diseases 3Health News:Stem Cells Hold Promise for Treating Neurodegenerative Diseases 4Health News:Stem Cells Hold Promise for Treating Neurodegenerative Diseases 5Health News:Soy Isoflavones Linked to Lower Prostate Cancer Risk 2
Nitinol Tipless Stone Basket...
1.5 Fr Nitinol Tipless Stone Basket...
Rapid latex agglutination test for presumptive identification of E. coli serogroup O157:H7 isolates. Colorimetric with red O157 latex and blue H7 latex....
For presumptive identification of Escherichia coli using enzyme technology. Tests: Indole, MUG...
Medicine Products: